SpringWorks Therapeutics (SWTX) Scheduled to Post Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is set to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.20). The company had revenue of $5.45 million during the quarter, compared to the consensus estimate of $1.26 million. During the same quarter last year, the company posted ($1.19) earnings per share. On average, analysts expect SpringWorks Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SpringWorks Therapeutics Trading Down 1.4 %

Shares of NASDAQ SWTX opened at $43.38 on Thursday. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -8.44 and a beta of 0.83. SpringWorks Therapeutics has a 1-year low of $18.00 and a 1-year high of $53.92. The stock’s 50-day moving average is $47.83 and its 200 day moving average is $37.56.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SWTX shares. JPMorgan Chase & Co. raised their price objective on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Barclays raised their price objective on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Guggenheim began coverage on SpringWorks Therapeutics in a report on Monday, February 5th. They set a “buy” rating and a $75.00 price objective on the stock. Wedbush raised their price target on SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 26th. Finally, HC Wainwright raised their price target on SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $68.00.

Insider Buying and Selling

In other news, insider Daniel Pichl sold 15,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $50.10, for a total value of $751,500.00. Following the sale, the insider now directly owns 45,212 shares in the company, valued at approximately $2,265,121.20. The sale was disclosed in a filing with the SEC, which is available through this link. 7.61% of the stock is owned by corporate insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.